Marinus Pharmaceuticals(MRNS) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results ● ZTALMY® (ganaxolone) Q2 2024 net product revenue of $8.0 million representing strong growth of 87% versus Q2 2023 ● On track to achieve full year 2024 ZTALMY net product revenue guidance of between $33 and $35 million ● Completed enrollment in the Phase 3 TrustTSC trial of oral ganaxolone in tuberous sclerosis complex (TSC) with topline data expected in the first half of Q4 2024 ● Expanded ZTALM ...